



17

PATENT
Customer No. 22,852
Attorney Docket No. 9762.0001-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Cara A. PELLEGRINI et al.) Group Art Unit: 1614
)
Application No.: 10/645,840) Examiner: Not Yet Assigned
)
Filed: August 22, 2003) Confirmation No.: 8135
)
For: METHOD OF INCREASING THE)
EXTENT OF ABSORPTION OF)
TIZANIDINE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Please find enclosed the following documents


1. PTO/SB/81- Power of Attorney and Correspondence Address Indication Form
2. PTO/SB/96- Statement Under 37 CFR 3.73(b)
 - a. Copy of Assignment from Cara Pellegrini to Elan Pharmaceuticals, Inc.
 - b. Copy of Assignment from Paul Stark to Elan Pharmaceuticals, Inc.
 - c. Copy of Assignment from Elan Pharmaceuticals, Inc to Acorda Therapeutics Inc.
3. PTO 1595 Recordation Form Cover Sheet
 - a. Copy of Assignment from Cara Pellegrini to Elan Pharmaceuticals, Inc.
 - b. Copy of Assignment from Paul Stark to Elan Pharmaceuticals, Inc.

4. PTO 1595 Recordation Form Cover Sheet

- a. Copy of Assignment from Elan Pharmaceuticals, Inc to Acorda
Therapeutics Inc.

Please note that the Assignment from Elan Pharmaceuticals, Inc to Acorda
Therapeutics Inc. will also apply to active application 10/339,648, Attorney Docket No.
09762-0001-03000. The above referenced application is a continuation-in-part of
10/339,648.

Dated: November 15, 2005

By: 
Kendra S. Mattison
Reg. No. 55,436

PTO/SB/81 (11-04)

Approved for use through 11/30/2005, OMB 0851-0036

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/845,840
Filing Date	August 22, 2003
First Named Inventor	Cara A. PELLEGRINI et al.
Title	Method of Increasing the Extent ...
Art Unit	1814
Examiner Name	Unknown
Attorney Docket Number	8762-0001-01

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

22,852

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

22,852

OR

<input checked="" type="checkbox"/> Firm or Individual Name	Finnegan, Henderson, Farabow, Garrett & Dunner LLP			
Address	901 New York Avenue, N.W.			
City	Washington	State	DC	Zip 20001-4413
Country	USA			
Telephone	(202)408-4000	Fax	(202)408-4400	

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/98)

SIGNATURE of Applicant or Assignee of Record

Signature	<i>Jane Wasman</i>	Date	11-15-2005
Name	Jane Wasman, Executive Vice President, Gen. Counsel & Corp. Sec'y	Telephone	914-347-4300
Title and Company	Acorda Therapeutics, Inc., 15 Skyline Drive, Hawthorne, New York 10532		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ *Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/88 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Pellegrini, Cara A., Stark, PaulApplication No./Patent No.: 10/645,840 Filed/Issue Date: August 22, 2003Entitled: METHOD OF TIZANIDINE THERAPY (AMENDED)Acorda Therapeutics, Inc.

a

Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Cara A. Pellegrini To: Elan Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: Paul Stark To: Elan Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: Elan Pharmaceuticals, Inc. To: Acorda Therapeutics, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Jane Wasman

Signature

11-15-2005

Date

Jane Wasman

Printed or Typed Name

914-347-4300

Telephone Number

Executive Vice President, General Counsel & Corporate Secretary

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.